Actively Recruiting
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Led by Palvella Therapeutics, Inc. · Updated on 2026-04-27
15
Participants Needed
4
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
CONDITIONS
Official Title
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be 6 years or older
- Diagnosed with angiokeratoma
- Able and willing to comply with all protocol-related activities
- Willing and able to provide written informed consent
You will not qualify if you...
- Any significant concurrent condition that could adversely affect participation
- Any history of allergy or hypersensitivity to sirolimus, sirolimus-like medications, or PTX-022
- Patients deemed unwilling or unable to remain compliant with all tests, procedures, and study drug administration
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Unified Health
Sherman Oaks, California, United States, 91403
Not Yet Recruiting
2
Cleaver Medical Group
Dawsonville, Georgia, United States, 30534
Actively Recruiting
3
Vividia Dermatology
Las Vegas, Nevada, United States, 89148
Not Yet Recruiting
4
Epiphany Dermatology
Southlake, Texas, United States, 76092
Actively Recruiting
Research Team
E
Emily Cook
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here